NutriLeads announces positive outcome of proof-of-concept study in humans

Date: 24/11/2016

24 November 2016, Wageningen, The Netherlands. NutriLeads B.V. today announces the positive outcome of a proof of concept study in humans demonstrating that its lead ingredient IMPP-1 is safe, well tolerated and supports immune function in humans.The results of the first clinical proof-of-concept study with IMPP-1 in healthy volunteers were evaluated by an international group of key opinion leaders from industry and academia. The experts concluded that the results demonstrate excellent tolerability and safety characteristics and significant and dose dependent stimulation of the immune system. “The positive result in first proof of concept study in healthy volunteers provides the necessary confidence to go full speed ahead with our ambitious development program including several clinical trials to support the use of this proprietary ingredient from sustainable sources as dietary supplement and for application in specialized functional and medical food products” indicates Ruud Albers, PhD, CEO of NutriLeads.